Early Combination Of Enbrel R etanercept And Methotrexate Halts Radiographic Progression In 90 Of Patients During Second Year Of The COMET Study
New data presented this week during the European League Against Rheumatism (EULAR) Annual Meeting in Copenhagen demonstrated that sustained combination therapy (etanercept and methotrexate) was consistently superior to continuous methotrexate monotherapy in providing clinical remission and radiographic non-progression over two years in patients with early active rheumatoid arthritis.1 These new data add to the body of evidence supporting the benefits of early intervention with a biologic treatment in patients with rheumatoid arthritis. The new data from the COMET (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) study show the percentage of patients in clinical remission after two years was significantly greater in the continued combination therapy (EM/EM) and delayed combination therapy groups (M/EM), than in the continued methotrexate monotherapy group (M/M) - 57% and 58% vs 35% (p<0.
When a patient's first symptoms of rheumatoid arthritis (RA) occur in winter, the severity of their RA (as measured by the modified Total Sharp Score, mTSS, an assessment of erosion and joint space narrowing) was rated more severe at six months, when compared to patients whose RA first became symptomatic in summer (Odds Ratio (OR) =2.82 [1.14; 7], p=0.0255). Furthermore, RA patients with their first symptoms in spring showed poorer radiographic outcome compared to summer-onset patients (OR=2.83 [1.10; 7.37], p=0.0322), according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.
First line treatment with anakinra (an interleukin-1 (IL-1) receptor antagonist), results in a 'good' clinical response (ACRp90) in patients newly diagnosed with systemic onset juvenile idiopathic arthritis (SoJIA), and restores the deficient IL-18 response of natural killer (NK) cells*, according to a new study presented recently at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark. During the six month study, numbers of NK cells slightly increased initially but remained stable throughout treatment with anakinra, although specific lysis (the death of a cell by breaking of the cellular membrane) was restored to normal within just three days.
Researchers, doctors and patient groups will today call on rheumatologists and related healthcare professionals to view their patients as productive workers and make their staying in work an important outcome in managing their condition. Musculoskeletal Disorders (MSDs) in Europe account for 50% of all work-related disorders and 60% of permanent work incapacity in the EU. At a Symposium, entitled Fighting Musculoskeletal Diseases to keep the European population Fit for Work, and part of the 2009 congress of the European League Against Rheumatism in Copenhagen, delegates will hear a range of evidence showing that early intervention and effective management of MSDs improves work ability and benefits individuals, society and the economies they live in.
Bristol-Myers Squibb Company (NYSE: BMY) announced results of two ORENCIA ® (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR) currently being held in Copenhagen, Denmark. I. Phase IIb 100 trial (7 years) The first, a long-term extension (LTE) study, analysed ORENCIA's safety and efficacy profile over 7 years of treatment in rheumatoid arthritis (RA) patients who have had an inadequate response to methotrexate (MTX). Study design During the 1 year randomised, double-blind (DB) placebo controlled period of this Phase IIb study, 339 patients with active RA and an inadequate response to MTX were randomised to receive either ORENCIA plus MTX or placebo plus MTX.
Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients With Rheumatoid Arthritis, New Phase 2 Studies Show
Pfizer announced today that data from two new mid-stage clinical studies of the company's oral JAK-3 inhibitor, CP-690, 550, showed statistically significant response versus placebo for patients with rheumatoid arthritis (RA). Data from these two Phase 2 trials and one ongoing open-label safety study are being presented this week at the 10th Annual Congress of the European League Against Rheumatism (EULAR). These results confirm findings from two previously reported Phase 2 studies in RA and have been used to support dose selection for Phase 3. Dose-Ranging with CP-690, 550 Alone Data presented from a 12-week interim analysis of a six-month, double-blind, placebo-controlled study (Study A3921035), which evaluated 384 patients with active RA who had not responded to a disease-modifying anti-rheumatic drug (DMARD), such as methotrexate, showed that patients treated with 5, 10 and 15 mg twice-daily doses of CP-690, 550 experienced statistically significantly superior outcomes compared to placebo.